134 related articles for article (PubMed ID: 15001234)
1. [Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases].
Montana M; Chochoi N; Monges P; Ravaux I; Faraut F; Gensollen S; Bongrand MC; Timon-David P; Gallais H
Pathol Biol (Paris); 2004 Mar; 52(2):66-75. PubMed ID: 15001234
[TBL] [Abstract][Full Text] [Related]
2. Visceral leishmaniasis treatment, Italy.
Gradoni L; Gramiccia M; Scalone A
Emerg Infect Dis; 2003 Dec; 9(12):1617-20. PubMed ID: 14720406
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
Minodier P; Retornaz K; Horelt A; Garnier JM
Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
[TBL] [Abstract][Full Text] [Related]
5. [Visceral leishmaniasis associated with human immunodeficiency virus infection].
Pintado V; López-Vélez R
Enferm Infecc Microbiol Clin; 2001; 19(7):353-7. PubMed ID: 11747803
[No Abstract] [Full Text] [Related]
6. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
8. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
Gradoni L; Gramiccia M; Scalone A
Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
[TBL] [Abstract][Full Text] [Related]
9. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
10. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001).
Pagliano P; Rossi M; Rescigno C; Altieri S; Coppola MG; Gramiccia M; Scalone A; Gradoni L; Faella F
J Antimicrob Chemother; 2003 Aug; 52(2):264-8. PubMed ID: 12865389
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy.
Berenguer J; Cosín J; Miralles P; López JC; Padilla B
AIDS; 2000 Dec; 14(18):2946-8. PubMed ID: 11153679
[No Abstract] [Full Text] [Related]
12. Treatment Options for Visceral Leishmaniasis and HIV Coinfection.
Monge-Maillo B; López-Vélez R
AIDS Rev; 2016; 18(1):32-43. PubMed ID: 26936761
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
[TBL] [Abstract][Full Text] [Related]
14. [Relapse of visceral leishmaniasis in HIV infection. Benefit of amphotericin B].
Kilani B; Amari L; Belhaj S; Goubontini A; Ben Chaabene T
Tunis Med; 2004 Mar; 82(3):316-9. PubMed ID: 15382468
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
16. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
[TBL] [Abstract][Full Text] [Related]
17. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
20. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
